Youli Zu

Summary

Affiliation: The Methodist Hospital
Country: USA

Publications

  1. pmc Transfection of shRNA-encoding Minivector DNA of a few hundred base pairs to regulate gene expression in lymphoma cells
    N Zhao
    Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, Houston, TX 77030, USA
    Gene Ther 18:220-4. 2011
  2. pmc Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126
    M Ito
    Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, Houston, TX 77030, USA
    Cancer Gene Ther 17:633-44. 2010
  3. pmc Interleukin-2 Functions in Anaplastic Large Cell Lymphoma Cells through Augmentation of Extracellular Signal-Regulated Kinases 1/2 Activation
    Masanori Ito
    Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, Houston, TX, USA
    Int J Biomed Sci 7:181-90. 2011
  4. pmc MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
    Shimin Hu
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 121:4021-31; quiz 4250. 2013
  5. pmc MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program
    Zijun Y Xu-Monette
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
    Blood 122:2630-40. 2013
  6. pmc Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study
    Carlo Visco
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Haematologica 98:255-63. 2013
  7. pmc CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
    Shimin Hu
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Blood 121:2715-24. 2013
  8. doi request reprint Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition
    Jianguo Wen
    Department of Pathology, The Methodist Hospital and Research Institute, Houston, TX 77030, USA
    Leuk Res 34:85-92. 2010
  9. doi request reprint Combination of an aptamer probe to CD4 and antibodies for multicolored cell phenotyping
    Peng Zhang
    Department of Pathology, The Methodist Hospital, Houston, TX 77030, USA
    Am J Clin Pathol 134:586-93. 2010
  10. doi request reprint Unique biomechanical interactions between myeloma cells and bone marrow stroma cells
    Yongdong Feng
    Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, 6565 Fannin, MS205, Houston, TX 77030, USA
    Prog Biophys Mol Biol 103:148-56. 2010

Collaborators

Detail Information

Publications26

  1. pmc Transfection of shRNA-encoding Minivector DNA of a few hundred base pairs to regulate gene expression in lymphoma cells
    N Zhao
    Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, Houston, TX 77030, USA
    Gene Ther 18:220-4. 2011
    ..Based on these results, Minivector DNAs are a promising new gene therapy tool...
  2. pmc Synergistic growth inhibition of anaplastic large cell lymphoma cells by combining cellular ALK gene silencing and a low dose of the kinase inhibitor U0126
    M Ito
    Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, Houston, TX 77030, USA
    Cancer Gene Ther 17:633-44. 2010
    ..Our findings indicate that combining cellular ALK gene silencing with a low dose of U0126 may prove to be an effective and more specific therapeutic approach to treating ALCL...
  3. pmc Interleukin-2 Functions in Anaplastic Large Cell Lymphoma Cells through Augmentation of Extracellular Signal-Regulated Kinases 1/2 Activation
    Masanori Ito
    Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, Houston, TX, USA
    Int J Biomed Sci 7:181-90. 2011
    ..Our findings demonstrate that IL-2 signaling plays a functional role in ALCL cells, and enhances lymphoma cell survival by increasing activation of the ERK1/2 pathway...
  4. pmc MYC/BCL2 protein coexpression contributes to the inferior survival of activated B-cell subtype of diffuse large B-cell lymphoma and demonstrates high-risk gene expression signatures: a report from The International DLBCL Rituximab-CHOP Consortium Program
    Shimin Hu
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA
    Blood 121:4021-31; quiz 4250. 2013
    ..In conclusion, the data suggest that MYC/BCL2 coexpression, rather than cell-of-origin classification, is a better predictor of prognosis in patients with DLBCL treated with R-CHOP...
  5. pmc MDM2 phenotypic and genotypic profiling, respective to TP53 genetic status, in diffuse large B-cell lymphoma patients treated with rituximab-CHOP immunochemotherapy: a report from the International DLBCL Rituximab-CHOP Consortium Program
    Zijun Y Xu-Monette
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX
    Blood 122:2630-40. 2013
    ....
  6. pmc Patients with diffuse large B-cell lymphoma of germinal center origin with BCL2 translocations have poor outcome, irrespective of MYC status: a report from an International DLBCL rituximab-CHOP Consortium Program Study
    Carlo Visco
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
    Haematologica 98:255-63. 2013
    ..BCL2 translocated germinal center subtype patients have worse prognosis after rituximab-CHOP, irrespective of MYC status, but the presence of combined gene breaks significantly overcomes the prognostic relevance of isolated lesions...
  7. pmc CD30 expression defines a novel subgroup of diffuse large B-cell lymphoma with favorable prognosis and distinct gene expression signature: a report from the International DLBCL Rituximab-CHOP Consortium Program Study
    Shimin Hu
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Blood 121:2715-24. 2013
    ....
  8. doi request reprint Enhanced antimyeloma cytotoxicity by the combination of arsenic trioxide and bortezomib is further potentiated by p38 MAPK inhibition
    Jianguo Wen
    Department of Pathology, The Methodist Hospital and Research Institute, Houston, TX 77030, USA
    Leuk Res 34:85-92. 2010
    ..The results suggest the opportunity for using p38 MAPK inhibition to enhance the efficacy of ATO+bortezomib in myeloma...
  9. doi request reprint Combination of an aptamer probe to CD4 and antibodies for multicolored cell phenotyping
    Peng Zhang
    Department of Pathology, The Methodist Hospital, Houston, TX 77030, USA
    Am J Clin Pathol 134:586-93. 2010
    ..Multicolored flow cytometry analysis revealed that the CD4 aptamer could be combined with antibodies to phenotype cells from bone marrow, lymph nodes, and pleural fluid, suggesting that the aptamer probe has value for clinical use...
  10. doi request reprint Unique biomechanical interactions between myeloma cells and bone marrow stroma cells
    Yongdong Feng
    Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, 6565 Fannin, MS205, Houston, TX 77030, USA
    Prog Biophys Mol Biol 103:148-56. 2010
    ..The increase of stiffness may in turn support the growth of myeloma cells and myeloma stem cells...
  11. doi request reprint A systematic modeling study on the pathogenic role of p38 MAPK activation in myelodysplastic syndromes
    Huiming Peng
    Department of Radiology, The Methodist Hospital, The Methodist Hospital Research Institute, and Weill Cornell Medical College, Houston, TX, USA
    Mol Biosyst 8:1366-74. 2012
    ..Our study suggests that the combination of molecular biological studies and systematic modeling is a powerful tool for comprehensive investigation of the complex cellular mechanisms involved in MDS pathogenesis...
  12. doi request reprint Luteinizing Hormone-Releasing Hormone (LHRH)-I antagonist cetrorelix inhibits myeloma cell growth in vitro and in vivo
    Jianguo Wen
    Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, 6565 Fannin MS205, Houston, TX 77030, USA
    Mol Cancer Ther 10:148-58. 2011
    ..Our findings indicate that Cetrorelix induces cytotoxicity in myeloma cells through various mechanisms and provide a rationale for investigating Cetrorelix for the treatment of MM...
  13. pmc Transfecting the hard-to-transfect lymphoma/leukemia cells using a simple cationic polymer nanocomplex
    Nianxi Zhao
    Department of Pathology and Genomic Medicine, The Methodist Hospital and The Methodist Hospital Research Institute, Houston, TX 77030, USA
    J Control Release 159:104-10. 2012
    ..These findings demonstrated a simple, efficient method for in vitro gene delivery into hard-to-transfect cells. The nanocomplexes are biodegradable and have minimal cytotoxicity, suggesting the potential use for in vivo gene delivery...
  14. doi request reprint Bone marrow stromal cells from myeloma patients support the growth of myeloma stem cells
    Yongdong Feng
    Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, Houston, Texas 77030, USA
    Stem Cells Dev 19:1289-96. 2010
    ..These findings indicate that the myeloma BMSCs create a microenvironment supportive of myeloma stem cells via, at least partially, the CXCR4 signaling pathway...
  15. pmc Using oligonucleotide aptamer probes for immunostaining of formalin-fixed and paraffin-embedded tissues
    Zihua Zeng
    Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, Houston, TX 77030, USA
    Mod Pathol 23:1553-8. 2010
    ..Therefore, our findings indicate that the synthetic oligonucleotide CD30 aptamer can be used as a probe for immunostaining of fixed tissue sections for disease diagnosis...
  16. pmc Using an RNA aptamer probe for flow cytometry detection of CD30-expressing lymphoma cells
    Peng Zhang
    Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, Houston, TX 77030, USA
    Lab Invest 89:1423-32. 2009
    ..In conclusion, the developed CD30 aptamer probe could act as a replacement and/or a supplement for antibodies in the diagnosis of the CD30-expressing lymphomas...
  17. pmc Biostable ssDNA aptamers specific for Hodgkin lymphoma
    Parag Parekh
    Department of Pathology and Genomic Medicine, Houston Methodist Hospital, and Cancer Pathology Research Laboratory, Houston Methodist Research Institute, Houston, TX 77030, USA
    Sensors (Basel) 13:14543-57. 2013
    ..Moreover, due to the inherent properties of DNA, the aptamers were stable in human serum, suggesting potential for in vivo detection of HL tumor cells. ..
  18. doi request reprint p38 mitogen-activated protein kinase has different degrees of activation in myeloproliferative disorders and myelodysplastic syndromes
    Munir Shahjahan
    Department of Pathology, Methodist Hospital and Methodist Research Institute, Houston, TX, USA
    Am J Clin Pathol 130:635-41. 2008
    ..007) cases. Increased p38 MAPK activation may have a role in inhibiting hematopoiesis leading to cytopenias in MDS, and relatively decreased p38 activation in MPD might promote hematopoiesis, resulting in cytosis...
  19. pmc Immunotherapy of CD30-expressing lymphoma using a highly stable ssDNA aptamer
    Parag Parekh
    Department of Pathology and Genomic Medicine, Houston Methodist Hospital, 6565 Fannin St, Houston, TX 77030, USA
    Biomaterials 34:8909-17. 2013
    ..Immunotherapy using aptamer-based co-stimulation provides an alternative to antibodies, and has potential to transform cancer treatment. ..
  20. doi request reprint Differentiating between Burkitt lymphoma and CD10+ diffuse large B-cell lymphoma: the role of commonly used flow cytometry cell markers and the application of a multiparameter scoring system
    Paul McGowan
    Pathology and Laboratory Medicine, The Methodist Hospital, Houston, TX, USA
    Am J Clin Pathol 137:665-70. 2012
    ..04; χ(2)). Our findings indicate that routine FC parameters can aid in differentiating BL from CD10+ DLBCL...
  21. pmc An ultra pH-sensitive and aptamer-equipped nanoscale drug-delivery system for selective killing of tumor cells
    Nianxi Zhao
    Department of Pathology and Genomic Medicine, The Methodist Hospital and Cancer Pathology Laboratory, The Methodist Hospital Research Institute, 6565 Fannin Street, Houston, TX 77030, USA
    Small 9:3477-84. 2013
    ....
  22. doi request reprint P38 MAPK inhibition enhancing ATO-induced cytotoxicity against multiple myeloma cells
    Jianguo Wen
    Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, Houston, TX, USA
    Br J Haematol 140:169-80. 2008
    ..These results suggest that ATO-induced p38 MAPK activation plays an important role in the resistance to ATO in myeloma cells and that p38 MAPK inhibition may overcome resistance to ATO treatment in myeloma patients...
  23. pmc A nanocomplex that is both tumor cell-selective and cancer gene-specific for anaplastic large cell lymphoma
    Nianxi Zhao
    Department of Pathology, The Methodist Hospital and The Methodist Hospital Research Institute, Houston, TX 77030, USA
    J Nanobiotechnology 9:2. 2011
    ..However, siRNAs are not cell type-selective, cannot specifically target tumor cells, and therefore have limited in vivo application for siRNA-mediated gene therapy...
  24. pmc Blocking interaction of viral gp120 and CD4-expressing T cells by single-stranded DNA aptamers
    Nianxi Zhao
    Department of Pathology and Genomic Medicine, Houston Methodist Hospital, and Cancer Pathology Laboratory, Houston Methodist Research Institute, 6565 Fannin Street, Houston, TX 77030, USA
    Int J Biochem Cell Biol 51:10-8. 2014
    ..These findings provide a new approach to prevent HIV-1 transmission using oligonucleotide aptamers. ..
  25. pmc Mutational profile and prognostic significance of TP53 in diffuse large B-cell lymphoma patients treated with R-CHOP: report from an International DLBCL Rituximab-CHOP Consortium Program Study
    Zijun Y Xu-Monette
    Department of Hematopathology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030 4009, USA
    Blood 120:3986-96. 2012
    ..We conclude that assessment of TP53 mutation status is important for stratifying R-CHOP-treated patients into distinct prognostic subsets and has significant value in the design of future therapeutic strategies...
  26. doi request reprint Acute leukemia immunohistochemistry: a systematic diagnostic approach
    Randall J Olsen
    Department of Pathology, The Methodist Hospital, 6565 Fannin St, M227, Houston, TX 77030, USA
    Arch Pathol Lab Med 132:462-75. 2008
    ..Although no one marker is pathognomonic for one malignancy, a well-chosen panel of antibodies can efficiently aid the diagnosis and classification of acute leukemias...

Research Grants3

  1. Role of MAP kinases in anaplastic large cell lymphoma
    Youli Zu; Fiscal Year: 2007
    ..More importantly, the resultant findings may lead to therapeutic advances for ALCL by identifying key signaling molecules in the lymphoma cells. ..
  2. A bifunctional nanomedicine for both specific imaging and targeting therapy of an
    Youli Zu; Fiscal Year: 2010
    ..In addition, it should enable physicians to in vivo image ALCL tumors and monitor therapeutic responses in a real-time manner. ..